Full Text Journal Articles by
Author Pierre Fenaux

Advertisement

Find full text journal articles






Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.

Ursula Rochau, Igor Stojkov, Annette Conrads-Frank, Helena H Borba, Karin A Koinig, Marjan Arvandi, Corine van Marrewijk, Hege Garelius, Ulrich Germing, Argiris Symeonidis, Guillermo F Sanz, Pierre Fenaux, Theo de Witte, Fabio Efficace, Uwe Siebert, Reinhard Stauder,

Treatment options for myelodysplastic syndromes (MDS) vary widely, depending on the natural disease course and patient-related factors. Comparison of treatment effectiveness is challenging as different endpoints have been included in clinical trials and outcome reporting. Our goal was to develop the first MDS core outcome set (MDS-COS) defining a minimum ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.

Pierre Peterlin, Thomas Cluzeau, Maxime Jullien, Anne-Marie Ngo Nloga, Anne Calleja, Eurydice Angeli, Patrice Chevallier, Thierry Guillaume, Alice Garnier, Amandine Le Bourgeois, Steven Le Gouill, Pierre Fenaux, Lionel Adès, Cécile Bally,

Br. J. Haematol. (British journal of haematology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM).

Luca Malcovati, Kristen Stevenson, Elli Papaemmanuil, Donna Neuberg, Rafael Bejar, Jacqueline Boultwood, David T Bowen, Peter J Campbell, Benjamin L Ebert, Pierre Fenaux, Torsten Haferlach, Michael Heuser, Joop H Jansen, Rami S Komrokji, Jaroslaw P Maciejewski, Matthew J Walter, Michaela Fontenay, Guillermo Garcia-Manero, Timothy A Graubert, Aly Karsan, Manja Meggendorfer, Andrea Pellagatti, David A Sallman, Michael R Savona, Mikkael Sekeres, David P Steensma, Sudhir Tauro, Felicitas Thol, Paresh Vyas, Arjan A Van de Loosdrecht, Detlef Thomas Haase, Heinz Tuechler, Peter L Greenberg, Seishi Ogawa, Eva S Hellstrom-Lindberg, Mario Cazzola,

The 2016 revision of the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues is characterized by a closer integration of morphology and molecular genetics. Notwithstanding, the myelodysplastic syndrome (MDS) with isolated del(5q) remains so far the only MDS subtype defined by a genetic abnormality. About half ... Read more >>

Blood (Blood)
[2020, :]

Cited: 0 times

View full text PDF listing >>



MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.

Pau Montesinos, Benjamin M Beckermann, Olivier Catalani, Jordi Esteve, Katia Gamel, Marina Y Konopleva, Giovanni Martinelli, Annabelle Monnet, Cristina Papayannidis, Aaron Park, Christian Récher, Rebeca Rodríguez-Veiga, Christoph Röllig, Norbert Vey, Andrew H Wei, Sung-Soo Yoon, Pierre Fenaux,

Patients with refractory or relapsed acute myeloid leukemia (R/R AML) have a poor prognosis, with a high unmet medical need. Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53. By preventing the p53-MDM2 interaction, idasanutlin allows for p53 activation, particularly in patients with TP53 wild-type ... Read more >>

Future Oncol (Future Oncology)
[2020, 16(13):807-815]

Cited: 0 times

View full text PDF listing >>



Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide.

Vera Adema, Laura Palomo, Andrea Toma, Olivier Kosmider, Francisco Fuster-Tormo, Rocío Benito, Rocío Salgado, Esperanza Such, María José Larrayoz, Blanca Xicoy, Jesus Maria Hernandez-Sanchez, Paolo Maietta, Alexander Neef, Michaela Fontenay, Mariam Ibañez, Maria Diez-Campelo, Sara Alvarez, Jaroslaw P Maciejewski, Pierre Fenaux, Francesc Sole,

Br. J. Haematol. (British journal of haematology)
[2020, 189(4):e133-e137]

Cited: 0 times

View full text PDF listing >>



Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman.

Claire Cochet, Marion Simonet, Julie Cattin, Jean-Patrick Metz, Ana Berceanu, Eric Deconinck, Etienne Daguindau, Françoise Schillinger, Pierre Fenaux, Nicolas Mottet, Yohan Desbrosses,

Acute leukemia during pregnancy is rare (1 for 100000 pregnancies). The association of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is known as the best therapy in standard-risk acute promyelocytic leukemia (APL). We describe the first case of a pregnancy with ATRA and ATO reported in the literature. In ... Read more >>

Case Rep Hematol (Case reports in hematology)
[2020, 2020:3686584]

Cited: 0 times

View full text PDF listing >>



Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.

Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Barry Skikne, C L Beach, Jerry Weaver, Nora Tu, Pierre Fenaux,

In the randomized, phase 3, MDS-005 study (NCT01029262), lenalidomide-induced red blood cell transfusion independence (RBC-TI) in 27% of transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes (MDS) ineligible for or refractory to erythropoiesis-stimulating agents. To determine the influence of erythropoietin (EPO) level on response, 155 patients treated with lenalidomide in MDS-005 ... Read more >>

Leuk. Lymphoma (Leukemia & lymphoma)
[2020, :1-9]

Cited: 0 times

View full text PDF listing >>



Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Sabine Kayser, Ramy Rahmé, David Martínez-Cuadrón, Gabriel Ghiaur, Xavier Thomas, Marta Sobas, Agnes Guerci-Bresler, Ana Garrido, Arnaud Pigneux, Cristina Gil, Emmanuel Raffoux, Mar Tormo, Norbert Vey, Javier de la Serna, Olga Salamero, Eva Lengfelder, Mark J Levis, Pierre Fenaux, Miguel A Sanz, Uwe Platzbecker, Richard F Schlenk, Lionel Adès, Pau Montesinos,

Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during consolidation (CTX/ATRA/ATO; n = 148), or with CTX/ATRA ... Read more >>

Leukemia (Leukemia)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.

Ana Rio-Machin, Tom Vulliamy, Nele Hug, Amanda Walne, Kiran Tawana, Shirleny Cardoso, Alicia Ellison, Nikolas Pontikos, Jun Wang, Hemanth Tummala, Ahad Fahad H Al Seraihi, Jenna Alnajar, Findlay Bewicke-Copley, Hannah Armes, Michael Barnett, Adrian Bloor, Csaba Bödör, David Bowen, Pierre Fenaux, Andrew Green, Andrew Hallahan, Henrik Hjorth-Hansen, Upal Hossain, Sally Killick, Sarah Lawson, Mark Layton, Alison M Male, Judith Marsh, Priyanka Mehta, Rogier Mous, Josep F Nomdedéu, Carolyn Owen, Jiri Pavlu, Elspeth M Payne, Rachel E Protheroe, Claude Preudhomme, Nuria Pujol-Moix, Aline Renneville, Nigel Russell, Anand Saggar, Gabriela Sciuccati, David Taussig, Cynthia L Toze, Anne Uyttebroeck, Peter Vandenberghe, Brigitte Schlegelberger, Tim Ripperger, Doris Steinemann, John Wu, Joanne Mason, Paula Page, Susanna Akiki, Kim Reay, Jamie D Cavenagh, Vincent Plagnol, Javier F Caceres, Jude Fitzgibbon, Inderjeet Dokal,

The inclusion of familial myeloid malignancies as a separate disease entity in the revised WHO classification has renewed efforts to improve the recognition and management of this group of at risk individuals. Here we report a cohort of 86 acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) families with 49 ... Read more >>

Nat Commun (Nature communications)
[2020, 11(1):1044]

Cited: 0 times

View full text PDF listing >>



Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, Yasuhito Nannya, Robert Hasserjian, Sean Devlin, Heinz Tuechler, Juan Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max Levine, Juan Arango, Yangyu Zhou, Francesc Sole, Catherine Cargo, Detlef Haase, Maria Creignou, Ulrich Germing, Yanming Zhang, Gunes Gundem, Araxe Sarian, Arjan van de Loosdrecht, Martin Jädersten, Magnus Tobiasson, Olivier Kosmider, Matilde Follo, Felicitas Thol, Ronald Pinheiro, Valeria Santini, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio P.S. Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori-Kondo, Toru Kiguchi, Chantana Polprasert, John Bennett, Virginia Klimek, Michael Savona, Monika Belickova, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Ades, Matteo Giovanni Della Porta, Alexandra Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna Neuberg, Kristen Stevenson, Kamal Menghrajani, Kelly Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin Ebert, Rafael Bejar, Peter Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil,

ABSTRACT TP53 mutations are associated with poor clinical outcomes and treatment resistance in myelodysplastic syndromes. However, the biological and clinical relevance of the underlying mono- or bi-allelic state of the mutations is unclear. We analyzed 3,324 MDS patients for TP53 mutations and allelic imbalances of the TP53 locus and found ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

Pierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, Guillermo Garcia-Manero, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Mario Cazzola, Osman Ilhan, Mikkael A Sekeres, José F Falantes, Beatriz Arrizabalaga, Flavia Salvi, Valentina Giai, Paresh Vyas, David Bowen, Dominik Selleslag, Amy E DeZern, Joseph G Jurcic, Ulrich Germing, Katharina S Götze, Bruno Quesnel, Odile Beyne-Rauzy, Thomas Cluzeau, Maria-Teresa Voso, Dominiek Mazure, Edo Vellenga, Peter L Greenberg, Eva Hellström-Lindberg, Amer M Zeidan, Lionel Adès, Amit Verma, Michael R Savona, Abderrahmane Laadem, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Diana R Dunshee, Peter G Linde, Matthew L Sherman, Rami S Komrokji, Alan F List,

BACKGROUND:Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study. METHODS:In a ... Read more >>

N. Engl. J. Med. (The New England journal of medicine)
[2020, 382(2):140-151]

Cited: 0 times

View full text PDF listing >>



Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase.

Justine Perino, Nathan Mottal, Yohann Bohbot, Vincent Servant, Aude Berroneau, Pierre Poustis, Pierre Fenaux, Kamel Laribi, Aude Charbonnier, Emilien Bilion, Claire Calmettes, Bernard Bégaud, Arnaud Pigneux, Noël Milpied, Ghada Miremont-Salamé, Hélène Théophile, Sophie Dimicoli-Salazar,

AIMS:Azacitidine (AZA), a pyrimidine analogue, is validated for high-risk myelodysplastic syndrome or low-blast acute myeloid leukaemia in unfit patients for more intensive treatment. This study assessed the putative link between cardiac failure (CF) and AZA exposure. METHODS:Cases of CF in patients treated with AZA were retrospectively collected and described from ... Read more >>

Br J Clin Pharmacol (British journal of clinical pharmacology)
[2020, 86(5):991-998]

Cited: 0 times

View full text PDF listing >>



Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Thomas Cluzeau, Nathan Furstoss, Coline Savy, Wejdane El Manaa, Marwa Zerhouni, Lauriane Blot, Anne Calleja, Maeva Dufies, Alix Dubois, Clemence Ginet, Nicolas Mounier, Georges Garnier, Sophie Raynaud, Pierre Simon Rohrlich, Pierre Peterlin, Aspasia Stamatoullas, Fatiha Chermat, Pierre Fenaux, Arnaud Jacquel, Guillaume Robert, Patrick Auberger,

Myelodysplastic syndrome (MDS) defines a group of heterogeneous hematologic malignancies that often progresses to acute myeloid leukemia (AML). The leading treatment for high-risk MDS patients is azacitidine (Aza, Vidaza®), but a significant proportion of patients are refractory and all patients eventually relapse after an undefined time period. Therefore, new therapies ... Read more >>

Int J Mol Sci (International journal of molecular sciences)
[2019, 21(1):]

Cited: 0 times

View full text PDF listing >>



Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.

Anne Sophie Kubasch, Freya Schulze, Aristoteles Giagounidis, Katharina S Götze, Jan Krönke, Katja Sockel, Jan Moritz Middeke, Fatiha Chermat, Silke Gloaguen, Martin Puttrich, Carmen Weigt, Doreen William, Pierre Fenaux, Richard F Schlenk, Christian Thiede, Sebastian Stasik, Anna Mies, Lionel Adès, Uta Oelschlägel, Uwe Platzbecker,

Leukemia (Leukemia)
[2020, 34(4):1182-1186]

Cited: 0 times

View full text PDF listing >>



Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review.

Anne Laure Roupie, Hubert de Boysson, Sara Thietart, Fabrice Carrat, Julie Seguier, Louis Terriou, Mathilde Versini, Viviane Queyrel, Matthieu Groh, Ygal Benhamou, Francois Maurier, Olivier Decaux, Maud d'Aveni, Julien Rossignol, Joris Galland, Eric Solary, Lise Willems, Nicolas Schleinitz, Lionel Ades, Azeddine Dellal, Maxime Samson, Achille Aouba, Pierre Fenaux, Olivier Fain, Arsène Mekinian, ,

INTRODUCTION:Myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms (MDS/MPN) can be associated with giant cell arteritis (GCA). In this nationwide study by the "French Network of dysimmune disorders associated with hemopathies" (MINHEMON) the objective was to evaluate characteristics, treatment and outcome of GCA MDS-MDS/MPN. PATIENTS AND METHODS:Retrospective analysis of patients that presented ... Read more >>

Autoimmun Rev (Autoimmunity reviews)
[2020, 19(2):102446]

Cited: 0 times

View full text PDF listing >>



Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.

Kathy L McGraw, Chia-Ho Cheng, Y Ann Chen, Hsin-An Hou, Björn Nilsson, Giulio Genovese, Thomas Cluzeau, Andrea Pellagatti, Bartlomiej P Przychodzen, Mar Mallo, Leonor Arenillas, Azim Mohamedali, Lionel Adès, David A Sallman, Eric Padron, Lubomir Sokol, Chimene Moreilhon, Sophie Raynaud, Hwei-Fang Tien, Jacqueline Boultwood, Benjamin L Ebert, Francesc Sole, Pierre Fenaux, Ghulam J Mufti, Jaroslaw P Maciejewski, Peter A Kanetsky, Alan F List,

Myelodysplastic syndromes (MDS) are hematopoietic stem cell malignancies. Known predisposing factors to adult MDS include rare germline mutations, cytotoxic therapy, age-related clonal hematopoiesis, and autoimmune or chronic inflammatory disorders. To date, no published studies characterizing MDS-associated germline susceptibility polymorphisms exist. We performed a genome-wide association study of 2 sample sets ... Read more >>

Blood Adv (Blood advances)
[2019, 3(22):3579-3589]

Cited: 0 times

View full text PDF listing >>



Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Nabih Maslah, Norman Salomao, Louis Drevon, Emmanuelle Verger, Nicolas Partouche, Pierre Ly, Philippe Aubin, Nadia Naoui, Marie-Helene Schlageter, Cecile Bally, Elsa Miekoutima, Rami Rahmé, Jacqueline Lehmann-Che, Lionel Ades, Pierre Fenaux, Bruno Cassinat, Stephane Giraudier,

Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine. PRIMA-1Met (APR-246, APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of the ... Read more >>

Haematologica (Haematologica)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Germline DDX41 mutations define a significant entity within adult MDS/AML patients.

Marie Sébert, Marie Passet, Anna Raimbault, Ramy Rahmé, Emmanuel Raffoux, Flore Sicre de Fontbrune, Marco Cerrano, Samuel Quentin, Nadia Vasquez, Mélanie Da Costa, Nicolas Boissel, Hervé Dombret, Régis Peffault de Latour, Gérard Socié, Raphaël Itzykson, Pierre Fenaux, Jean Soulier, Lionel Adès, Emmanuelle Clappier,

Germline DDX41 mutations are involved in familial myelodysplastic syndromes (MDSs) and acute myeloid leukemias (AMLs). We analyzed the prevalence and characteristics of DDX41-related myeloid malignancies in an unselected cohort of 1385 patients with MDS or AML. Using targeted next-generation sequencing, we identified 28 different germline DDX41 variants in 43 unrelated ... Read more >>

Blood (Blood)
[2019, 134(17):1441-1444]

Cited: 0 times

View full text PDF listing >>



How we manage adults with myelodysplastic syndrome.

Pierre Fenaux, Uwe Platzbecker, Lionel Ades,

The prognosis in Myelodysplastic syndromes (MDS), although recently refined by molecular studies, remains largely based on conventional prognostic scores [International Prognostic Scoring System (IPSS), revised IPSS], classifying patients into "lower risk" MDS (LR-MDS) and "higher risk" MDS (HR-MDS). In LR-MDS, treatment mainly aims at improving cytopenias, principally anaemia, while in ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with associated inflammatory state.

Sihem Tarfi, Bouchra Badaoui, Nicolas Freynet, Margot Morabito, Jeffie Lafosse, Andréa Toma, Gabriel Etienne, Jean-Baptiste Micol, Ivan Sloma, Pierre Fenaux, Eric Solary, Dorothée Selimoglu-Buet, Orianne Wagner-Ballon, ,

Haematologica (Haematologica)
[2019, :]

Cited: 1 time

View full text PDF listing >>



Non-allogeneic immunotherapy in acute myeloid leukaemia.

Lionel Adès, Marie Sébert, Pierre Fenaux,

Lancet Haematol (The Lancet. Haematology)
[2019, 6(9):e443-e444]

Cited: 0 times

View full text PDF listing >>



Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Marlijn Hoeks, Ge Yu, Saskia Langemeijer, Simon Crouch, Louise de Swart, Pierre Fenaux, Argiris Symeonidis, Jaroslav Čermák, Eva Hellström-Lindberg, Guillermo Sanz, Reinhard Stauder, Mette Skov Holm, Moshe Mittelman, Krzysztof Mądry, Luca Malcovati, Aurelia Tatic, Antonio Medina Almeida, Ulrich Germing, Aleksandar Savic, Njetočka Gredelj Šimec, Dominic Culligan, Raphael Itzykson, Agnes Guerci-Bresler, Borhane Slama, Jackie Droste, Corine van Marrewijk, Arjan van de Loosdrecht, Nicole Blijlevens, Marian van Kraaij, David Bowen, Theo de Witte, Alex Smith, ,

Iron overload due to red blood cell (RBC) transfusions is associated with morbidity and mortality in lower-risk myelodysplastic syndrome (MDS) patients. Many studies have suggested improved survival after iron chelation therapy (ICT), but valid data are limited. The aim of this study was to assess the effect of ICT on ... Read more >>

Haematologica (Haematologica)
[2020, 105(3):640-651]

Cited: 0 times

View full text PDF listing >>



Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation.

Pauline Bonnet, François Chasset, Philippe Moguelet, Noémie Abisror, Raphaël Itzykson, Jean-David Bouaziz, Pierre Hirsch, Annick Barbaud, Julien Haroche, Arsène Mekinian, Zofia Hélias-Rodzewicz, Emmanuelle Clappier, Pierre Fenaux, Olivier Fain, Abdellatif Tazi, Jean-François Emile, ,

Haematologica (Haematologica)
[2019, 104(11):e530-e533]

Cited: 0 times

View full text PDF listing >>



Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.

Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, Pierre Fenaux, Argiris Symeonidis, Jaroslav Cermâk, Eva Hellström-Lindberg, Reinhard Stauder, Guillermo Sanz, Moshe Mittelman, Mette Skov Holm, Luca Malcovati, Krzysztof Mądry, Ulrich Germing, Aurelia Tatic, Aleksandar Savic, Antonio Medina Almeida, Njetocka Gredelj-Simec, Agnes Guerci-Bresler, Odile Beyne-Rauzy, Dominic Culligan, Ioannis Kotsianidis, Raphael Itzykson, Corine van Marrewijk, Nicole Blijlevens, David Bowen, Theo de Witte, ,

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-monthly intervals from newly diagnosed lower-risk myelodysplastic syndromes patients in ... Read more >>

Haematologica (Haematologica)
[2020, 105(3):632-639]

Cited: 0 times

View full text PDF listing >>



Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made.

Lionel Adès, Marie Sebert, Pierre Fenaux,

Lancet Haematol (The Lancet. Haematology)
[2019, 6(6):e290-e291]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2975 s